MeiraGTx Holdings plc Ordinary Shares (MGTX) Stock
NASDAQ · MGTX
10.98
Fundamentals
Market cap
$1.05B
Price / Earnings ratio
13.4x
Price / Sales ratio
2.7x
Price / Book ratio
4.9x
Return on assets
-55.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates
NeutralMGTXAugust 13, 2026
Zacks Investment ResearchNeutral
MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates
MGTX

Zacks Investment Research
Wall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High?
NeutralMGTXJuly 15, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High?
MGTX

The Motley Fool
What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near
NeutralMGTXJuly 12, 2026
The Motley FoolNeutral
What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near
MGTX

Zacks Investment Research
MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last?
NeutralMGTXJuly 8, 2026
Zacks Investment ResearchNeutral
MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last?
MGTX
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral1
Buy2
Strong Buy0
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Zacks Investment Research
MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates
NeutralMGTXAugust 13, 2026
Zacks Investment ResearchNeutral
MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates
MGTX

Zacks Investment Research
Wall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High?
NeutralMGTXJuly 15, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High?
MGTX

The Motley Fool
What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near
NeutralMGTXJuly 12, 2026
The Motley FoolNeutral
What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near
MGTX

Zacks Investment Research
MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last?
NeutralMGTXJuly 8, 2026
Zacks Investment ResearchNeutral
MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last?
MGTX

Zacks Investment Research
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates
NeutralMGTXMay 14, 2026
Zacks Investment ResearchNeutral
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates
MGTX

Zacks Investment Research
Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know
NeutralMGTXMay 5, 2026
Zacks Investment ResearchNeutral
Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know
MGTX

Zacks Investment Research
MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?
NeutralMGTXApril 20, 2026
Zacks Investment ResearchNeutral
MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?
MGTX

Zacks Investment Research
Strength Seen in MeiraGTx (MGTX): Can Its 6.2% Jump Turn into More Strength?
NeutralMGTXMarch 31, 2026
Zacks Investment ResearchNeutral
Strength Seen in MeiraGTx (MGTX): Can Its 6.2% Jump Turn into More Strength?
MGTX

Zacks Investment Research
MeiraGTx Holdings PLC (MGTX) Q4 Earnings and Revenues Surpass Estimates
NeutralMGTXMarch 26, 2026
Zacks Investment ResearchNeutral
MeiraGTx Holdings PLC (MGTX) Q4 Earnings and Revenues Surpass Estimates
MGTX

Reuters
Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease
NeutralMGTXNovember 10, 2025
ReutersNeutral
Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease
MGTX
About MeiraGTx Holdings plc Ordinary Shares
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
SectorHealthcare
IndustryBiotechnology
Employees393
CEODr. Alexandria Forbes Ph.D.
IPO DateJun 8, 2018
HeadquartersNew York, NY
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Alexandria Forbes Ph.D. | CEO, President & Director | 1965 |
| Mr. Richard Brian Giroux B.A. | COO & CFO | 1974 |
| Dr. Robert K. Zeldin M.D. | Chief Medical Officer | 1963 |
| Mr. Robert J. Wollin J.D. | General Counsel & Secretary | 1976 |
| Dr. Stuart Naylor Ph.D. | Chief Scientific Officer of Ophthalmology | 1963 |
| Dr. Michel Michaelides F.A.C.S., M.D., MBBS | Head of Clinical Ophthalmology | — |
| Ms. Christine Elise Sheehy | Senior Vice President of Global Integration | 1968 |
| Mr. Tim Randall | Senior Vice President of Risk & Internal Controls | — |
| Dr. David Rubinstein Ph.D. | Senior Vice President of Business Development | — |
| Dr. Tassos Georgiadis Ph.D. | Senior Vice President of Discovery & Preclinical Development | — |
Fundamentals
Valuation
Market cap$1.05B
Price-to-sales ratio2.67
Price-to-book value4.92
Price-earnings ratio13.40
Return on Equity475.00%
Return on Sales-136.00%
Return on Assets-55.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$0.76
Income Statement
Average volume873,015
EBITDA$-96.06M
1 year high (52w)$15.35
1 year low (52w)$6.62
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
3 Wall Street Analyst Ratings
BUY
67% Buy
33% Hold
0% Sell
Target price
$21.00
Est return
93.55%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +13.6 | +1.4 | +13.2 | +37.9 | -7.9 | +16.2 | -23.1 |



